204 related articles for article (PubMed ID: 35666812)
61. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.
Zhang J; Wu T; Simon J; Takada M; Saito R; Fan C; Liu XD; Jonasch E; Xie L; Chen X; Yao X; Teh BT; Tan P; Zheng X; Li M; Lawrence C; Fan J; Geng J; Liu X; Hu L; Wang J; Liao C; Hong K; Zurlo G; Parker JS; Auman JT; Perou CM; Rathmell WK; Kim WY; Kirschner MW; Kaelin WG; Baldwin AS; Zhang Q
Science; 2018 Jul; 361(6399):290-295. PubMed ID: 30026228
[TBL] [Abstract][Full Text] [Related]
62. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
63. The von Hippel-Lindau Tumor Suppressor Gene Mutations Modulate Lipocalin-2 Expression in Ferroptotic-Inflammatory Pathways.
Kuo CY; Hsieh PC; Chiu V; Lan CC; Lu KC
Oxid Med Cell Longev; 2023; 2023():7736638. PubMed ID: 36718277
[TBL] [Abstract][Full Text] [Related]
64. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
65. [Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma].
Luu VD; Fischer B; von Teichman A; Boysen G; Mertz K; Zimmermann P; Moch H; Schraml P
Pathologe; 2008 Nov; 29 Suppl 2():303-7. PubMed ID: 18751980
[TBL] [Abstract][Full Text] [Related]
66. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma.
Kroeger N; Klatte T; Chamie K; Rao PN; Birkhäuser FD; Sonn GA; Riss J; Kabbinavar FF; Belldegrun AS; Pantuck AJ
Cancer; 2013 Apr; 119(8):1547-54. PubMed ID: 23335244
[TBL] [Abstract][Full Text] [Related]
67. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential
Mizutani K; Yokoi S; Sawada S; Sakamoto I; Kameyama K; Kamei S; Hirade K; Sugiyama S; Matsunaga K; Yamada T; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2022; 19(6):740-746. PubMed ID: 36316043
[TBL] [Abstract][Full Text] [Related]
68. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
69. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
[TBL] [Abstract][Full Text] [Related]
70. Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis.
Espana-Agusti J; Warren A; Chew SK; Adams DJ; Matakidou A
Nat Commun; 2017 Dec; 8(1):2026. PubMed ID: 29229903
[TBL] [Abstract][Full Text] [Related]
71. Does the VHL polymorphisms rs779805 and rs1642742 affect renal cell carcinoma susceptibility, prognosis and survival in Central European population?
Chrabańska M; Szweda-Gandor N; Drozdzowska B
Medicine (Baltimore); 2023 Dec; 102(50):e36540. PubMed ID: 38115281
[TBL] [Abstract][Full Text] [Related]
72. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
73. Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation.
Lehmann H; Vicari D; Wild PJ; Frew IJ
J Am Soc Nephrol; 2015 Nov; 26(11):2778-88. PubMed ID: 25788526
[TBL] [Abstract][Full Text] [Related]
74. Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours.
Ivanova AV; Vortmeyer A; Ivanov SV; Nickerson ML; Maher ER; Lerman MI
J Pathol; 2008 Jan; 214(1):46-57. PubMed ID: 17973242
[TBL] [Abstract][Full Text] [Related]
75. von Hippel-Lindau-dependent patterns of RNA polymerase II hydroxylation in human renal clear cell carcinomas.
Yi Y; Mikhaylova O; Mamedova A; Bastola P; Biesiada J; Alshaikh E; Levin L; Sheridan RM; Meller J; Czyzyk-Krzeska MF
Clin Cancer Res; 2010 Nov; 16(21):5142-52. PubMed ID: 20978146
[TBL] [Abstract][Full Text] [Related]
76. A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression.
Yang J; Luo L; Zhao C; Li X; Wang Z; Zeng Z; Yang X; Zheng X; Jie H; Kang L; Li S; Liu S; Zhou C; Liu H
Int J Biol Sci; 2022; 18(8):3470-3483. PubMed ID: 35637958
[TBL] [Abstract][Full Text] [Related]
77. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells.
Lutz MS; Burk RD
Cancer Res; 2006 Jul; 66(14):6903-7. PubMed ID: 16849532
[TBL] [Abstract][Full Text] [Related]
78. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.
Bailey ST; Smith AM; Kardos J; Wobker SE; Wilson HL; Krishnan B; Saito R; Lee HJ; Zhang J; Eaton SC; Williams LA; Manocha U; Peters DJ; Pan X; Carroll TJ; Felsher DW; Walter V; Zhang Q; Parker JS; Yeh JJ; Moffitt RA; Leung JY; Kim WY
Nat Commun; 2017 Jun; 8():15770. PubMed ID: 28593993
[TBL] [Abstract][Full Text] [Related]
79. Features of increased malignancy in eosinophilic clear cell renal cell carcinoma.
Nilsson H; Lindgren D; Axelson H; Brueffer C; Saal LH; Lundgren J; Johansson ME
J Pathol; 2020 Dec; 252(4):384-397. PubMed ID: 32815150
[TBL] [Abstract][Full Text] [Related]
80. A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding.
Robinson CM; Poon BPK; Kano Y; Pluthero FG; Kahr WHA; Ohh M
Mol Cancer Res; 2019 Nov; 17(11):2306-2317. PubMed ID: 31427440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
